10 analysts have expressed a variety of opinions on Macrogenics MGNX over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 5 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 3 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Macrogenics and provided 12-month price targets. The average target is $21.8, accompanied by a high estimate of $29.00 and a low estimate of $14.00. This current average reflects an increase of 48.3% from the previous average price target of $14.70.
Investigating Analyst Ratings: An Elaborate Study
The perception of Macrogenics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yigal Nochomovitz | Citigroup | Raises | Buy | $25.00 | $13.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Outperform | $22.00 | $16.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Neutral | $16.00 | $14.00 |
| Etzer Darout | BMO Capital | Raises | Outperform | $24.00 | $18.00 |
| Stephen Willey | Stifel | Raises | Buy | $29.00 | $17.00 |
| Peter Lawson | Barclays | Raises | Overweight | $25.00 | $23.00 |
| Kaveri Pohlman | BTIG | Raises | Buy | $24.00 | $12.00 |
| Peter Lawson | Barclays | Raises | Overweight | $23.00 | $12.00 |
| Robert Burns | HC Wainwright & Co. | Raises | Neutral | $14.00 | $12.00 |
| Silvan Tuerkcan | JMP Securities | Raises | Market Outperform | $16.00 | $10.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Macrogenics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Macrogenics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Macrogenics's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Macrogenics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Macrogenics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Macrogenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Understanding the Numbers: Macrogenics's Finances
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Macrogenics's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -87.12% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Macrogenics's net margin is impressive, surpassing industry averages. With a net margin of -502.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Macrogenics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -26.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Macrogenics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Macrogenics's debt-to-equity ratio surpasses industry norms, standing at 0.22. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
